Table 1.

Cytotoxicity toward HCL Patient Cells

EC50 ± SD (ng/mL)
patient	Moxetumomab pasudotox (HA22)	HA22-LR	HA22-LR/FUR	HA22-LR R279G	assay type
BL02	0.130 ± 0.003	0.150 ± 0.006	0.147 ± 0.003	<100	ATP
	0.368 ± 0.118	0.519 ± 0.135	0.402 ± 0.078	417 ± 100	Protein synthesis
C117***	0.140 ± 0.004	0.229 ± 0.007	0.128 ± 0.003	>1000	ATP
	0.142 ± 0.018	0.153 ± 0.026	0.132 ± 0.001	468 ± 46.3	Protein synthesis
HH20***	<0.1	0.232 ± 0.017	0.068 ± 0.023	<100	ATP
	<0.1	<0.1	0.094 ± 0.035	<100	Protein synthesis
RD27	0.784 ± 0.028	0.368 ± 0.040	0.352 ± 0.012	>1000	ATP
	0.532 ± 0.186	0.315 ± 0.092	0.237 ± 0.014	512 ± 352	Protein synthesis
HH01***	0.352 ± 0.002	0.449 ± 0.013	0.306 ± 0.005	>1000	ATP
	0.347 ± 0.016	0.441 ± 0.103	0.239 ± 0.039	>1000	Protein synthesis
C186***	0.416 ± 0.019	0.629 ± 0.018	0.997 ± 0.031	>1000	ATP
	0.456 ± 0.035	0.780 ± 0.161	0.872 ± 0.115	>1000	Protein synthesis

^***p < 0.001 from an unpaired two-tailed t test comparing the ATP-depletion assay results of HA22-LR and HA22-LR/FUR.